Pelthos Therapeutics Inc. PTHS 深 沪
等待开盘 11-06 09:30:00 美东时间
9.345
-0.805
-7.93%
华盛通- 最 高10.21
- 今 开10.16
- 成交量 2.85万股
- 最 低 9.33
- 昨 收 10.15
- 总市值 3577.70万
- 52周最高 34.68
- 市盈率 静 --
- 换手率 0.75%
- 52周最低 9.02
- 委 比 2.07%
- 总股本 382.85万
- 历史最高 60.00
- 量 比 0.28
- 振 幅 8.67%
- 历史最低 4.50
- 每 手 1
- 风险率 3.89%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多美股夜盘 | Pelthos Therapeutics Inc.暴泻43.17%，最新股价9.4美元
Pelthos Therapeutics Inc.暴泻43.17%，报9.4美元
11-02 09:15
Pelthos Therapeutics Strikes Business Combination Agreement With Castle Creek Biosciences; Shareholders Of Castle Creek Biosciences To Receive 5.2M Common Shares Of Pelthos
Pelthos Therapeutics Inc. (NYSE:PTHS) ("Pelthos" or the "Company"), a biopharmaceutical company committed to commercializing innovative therapeutic products for unmet patient needs, and Castle Creek Biosciences, Inc. ("Castle Creek"), a late-stage company developing redosable gene therapies, today a...
10-30 21:16
Pelthos Therapeutics to Combine with Castle Creek Biosciences, Creating Transformative Biotechnology Company Focused on Serious Diseases that Affect the Skin
Pelthos Therapeutics and Castle Creek Biosciences have agreed to merge, combining Pelthos' dermatology expertise with Castle Creek's fibroblast-based cell and gene therapy platform. The merger aims to advance treatments for rare skin diseases, with D-Fi, Castle Creek's lead candidate for dystrophic epidermolysis bullosa (DEB), receiving Orphan Drug Designation. The combined company will leverage Pelthos' commercial capabilities to accelerate D-Fi...
10-30 13:09
Pelthos Therapeutics Announces Expanded Formulary Coverage for ZELSUVMI® (berdazimer) Topical Gel, 10.3%
Pelthos Therapeutics announced new formulary coverage for ZELSUVMI, expanding access to 24 million additional lives through a major PBM and 3 million through a regional health plan. This brings total commercial coverage to 127 million lives and full Medicaid coverage. ZELSUVMI, a topical treatment for molluscum contagiosum, is the first at-home prescription therapy for the condition. The company emphasizes its commitment to improving patient acce...
10-06 12:00
Pelthos Therapeutics Earnings Call Highlights Strong Momentum
Pelthos Therapeutics Inc. (($PTHS)) has held its Q2 earnings call. Read on for ...
08-23 08:23
Pelthos Therapeutics to Report Second Quarter 2026 Financial Results on August 13, 2026
Pelthos Therapeutics Inc. will report its second quarter 2026 financial results on Thursday, August 13, 2026, followed by a conference call at 8:30 a.m. ET. Participants can join via phone using the toll-free number 1-877-451-6152 (US) or 1-201-389-0879 (international), using Conf.ID 13761132, or via the provided CallMe link. A webcast option is also available. Pelthos is a biopharmaceutical company focused on developing therapeutic products for ...
08-03 12:00
Pelthos Therapeutics Announces 2026 Annual Meeting of Stockholders
Pelthos Therapeutics Inc. announced its 2026 Annual Meeting of Stockholders will be held virtually on September 29, 2026, at 9:00 a.m. Eastern Time. Stockholders of record as of August 4, 2026, are entitled to vote. The meeting date differs by more than 30 days from the 2025 meeting, requiring stockholder proposals under Rule 14a-8 to be submitted by August 3, 2026. Pelthos, a commercial-stage biopharmaceutical company, focuses on developing trea...
07-24 21:00
Pelthos Therapeutics Joins The Russell 3000E Growth Benchmark, Russell Microcap And Russell Microcap Growth Benchmark Indexes
Pelthos Therapeutics Inc. (NYSE:PTHS), a biopharmaceutical company committed to commercializing innovative therapeutic products for unmet patient needs, ("Pelthos"), today announced that the company was added as a member of the Russell 3000E™ Growth Benchmark, Russell Microcap®, and Russell Microcap...
07-01 04:17
Pelthos Therapeutics Added to Russell 3000E™ Growth Benchmark, Russell Microcap® and Russell Microcap® Growth Benchmark Indexes
Pelthos Therapeutics Inc. was added to the Russell 3000E™ Growth Benchmark, Russell Microcap®, and Russell Microcap® Growth Benchmark Indexes effective June 29, 2026. The reconstitution captures the 4,000 largest U.S. stocks by market capitalization and occurs semi-annually. CEO Scott Plesha stated the inclusion reflects Pelthos' progress since becoming public and will enhance visibility in the investment community. Russell indexes, managed by FT...
06-30 20:15
Pelthos Therapeutics to Participate in 2026 Jefferies Global Healthcare Conference
Pelthos Therapeutics Inc. announced that CEO Scott Plesha will present at the Jefferies Global Healthcare Conference on June 4, 2026, in New York. The presentation will take place at 11:05 am ET, and Scott will also participate in one-on-one investor meetings. Investors interested in scheduling meetings should contact their Jefferies representative. Pelthos is a biopharmaceutical company focused on commercializing innovative therapies for unmet p...
05-28 21:00
